SS-31 peptide kidney research centers on mitochondrial protection in acute kidney injury and diabetic nephropathy. Here's what studies show so far.
SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide that researchers have studied as a way to protect kidney cells from energy failure and oxidative damage. The kidney evidence is still almost entirely preclinical, drawn from animal models of acute kidney injury, ischemia-reperfusion, and diabetic kidney disease. SS-31 is not FDA-approved for human use in the United States, and no approved product is indicated for kidney disease.
That gap between laboratory promise and clinical proof is the most important thing to understand before considering the compound. Below is what the research actually shows, the doses used in studies, and the safety and legal questions that remain open.
What SS-31 Is and Why the Kidney Is a Target
SS-31 is a short synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that concentrates on the inner mitochondrial membrane. There it binds cardiolipin, the phospholipid that helps organize the cristae where the electron transport chain produces ATP.
Kidney cells are unusually mitochondria-dependent. Proximal tubule cells reabsorb filtered sodium and need a constant ATP supply, so mitochondrial damage shows up quickly as falling kidney function. That biology is the reason researchers explore ss-31 peptide benefits in kidney models: protect the mitochondria and you may protect the tubule.
SS-31 remains an investigational compound. It has been tested in human trials for other conditions, but it is sold online only as a research chemical.
How SS-31 Affects Kidney Cells
The proposed mechanism is mitochondrial protection rather than immune suppression or direct diuresis. Reported effects in laboratory work include:
- Stabilizing cardiolipin and cristae structure on the inner mitochondrial membrane.
- Reducing cytochrome c peroxidase activity, which limits lipid peroxidation.
- Lowering mitochondrial reactive oxygen species without shutting down normal redox signaling.
- Preserving ATP production during ischemia and reperfusion.
- Reducing tubular cell apoptosis, inflammation, and fibrosis markers in injury models.
These findings come from cell cultures and animal studies. They do not establish that SS-31 reverses kidney disease in people.
What Kidney Research Shows So Far
Most published kidney data come from rodents. The pattern across studies is fairly consistent: treated animals show less tubular injury and better mitochondrial function than controls, but the models are short-term and the endpoints vary.
| Model | Reported SS-31 effect | Evidence level |
|---|---|---|
| Ischemia-reperfusion acute kidney injury (rats, mice) | Lower serum creatinine, less tubular necrosis, preserved mitochondrial respiration | Animal only |
| Cisplatin nephrotoxicity (mice) | Reduced proximal tubule apoptosis and oxidative damage | Animal only |
| Diabetic kidney disease (db/db and streptozotocin mice) | Less albuminuria, reduced mesangial expansion and fibrosis | Animal only |
| Sepsis-associated AKI (LPS models) | Improved mitochondrial function, lower injury biomarkers | Animal only |
| Human trials in Barth syndrome and primary mitochondrial myopathy | Mixed functional results; FDA declined approval for primary mitochondrial myopathy | Human, non-kidney indications |
No completed human trial has tested SS-31 as a kidney therapy with creatinine, dialysis, or disease-progression endpoints. That is why researchers describe the kidney case for SS-31 as promising but unproven.
SS-31 Dosage and Dosing Protocols Used in Research
There is no validated ss-31 peptide dosage for kidney disease in humans. Doses in the literature are preclinical, and animal doses do not translate directly to people because of differences in metabolism, clearance, and delivery to kidney tissue.
| Setting | Route | Typical reported dose | Notes |
|---|---|---|---|
| Rodent AKI and diabetic kidney studies | Subcutaneous | 1-5 mg/kg per day | Most common research regimen |
| Rodent ischemia-reperfusion protocols | Intravenous infusion | 0.05-1 mg/kg | Often given at reperfusion |
| Human trials, Barth syndrome and mitochondrial myopathy | Subcutaneous | 40 mg once daily | Non-kidney indications |
| Human heart failure trials | IV infusion | Weight-based infusion over several hours | Did not establish kidney benefit |
Anyone presenting a fixed ss-31 peptide dosing protocol for kidney patients is going beyond the published evidence. Route, timing, and duration matter as much as the milligram amount, and no human kidney dose has been established.
Side Effects, Safety, and Legal Status
In human trials for other conditions, the most frequently reported ss-31 peptide side effects were injection-site reactions, with occasional headache, nausea, or dizziness. Serious events were uncommon, but those trials enrolled relatively few patients and did not focus on people with kidney impairment.
- Long-term safety data are limited, and nobody knows how repeated dosing affects kidneys already under stress.
- Reduced kidney function changes how compounds are cleared, and unapproved peptides come with no dosing guidance for chronic kidney disease.
- Research-chemical products are not required to meet pharmaceutical purity or sterility standards.
- SS-31 is not FDA-approved for human use, so human use is unregulated and off-label.
If you have kidney disease, talk with a nephrologist before adding any peptide. Blood pressure control, glucose management, SGLT2 inhibitors, and other approved therapies have far stronger human evidence behind them.
Bodybuilding Claims, Online Vendors, and What to Check
SS-31 circulates in fitness communities as a recovery and endurance compound, and ss-31 peptide bodybuilding content sometimes claims it shields the kidneys during heavy training or high-protein diets. No human study supports those claims, and there is no evidence that SS-31 improves muscle growth or athletic performance.
If you are considering ss-31 peptide buy online research chemicals, check whether the seller publishes third-party certificates of analysis, states purity and endotoxin testing, and labels the product "not for human use." Vague marketing pages and unverifiable testimonials are common in this market.
The bottom line is straightforward. SS-31 is an interesting mitochondrial research peptide with encouraging animal kidney data, and it is not a proven or approved treatment for any kidney condition in humans.
Frequently Asked Questions
Does SS-31 actually help kidney disease in humans?
No human trial has shown that SS-31 treats or reverses kidney disease. Kidney benefits have been reported in rodent models of acute kidney injury and diabetic kidney disease, but human data are limited to trials in other conditions such as Barth syndrome and mitochondrial myopathy. SS-31 is not FDA-approved for any indication.
What dose of SS-31 is used in kidney research?
Rodent kidney studies typically use about 1 to 5 mg/kg per day given subcutaneously, or roughly 0.05 to 1 mg/kg by intravenous infusion in ischemia-reperfusion protocols. Human trials for non-kidney conditions used 40 mg subcutaneously once daily. No human kidney dose has been established.
Is SS-31 legal to buy in the United States?
SS-31 is sold online as a research chemical, not as an approved drug, so sellers label it "not for human use." Buying or possessing it for personal human use sits in a gray area, and the FDA has not approved elamipretide for any indication. Products from unregulated vendors may also contain impurities.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.